1,3-Diazo-4-Oxa-Bicyclic Derivatives Synthesis via Reducing Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing 1,3-diazo-4-oxa-[3.3.1]-bicyclic derivatives are inefficient, requiring long reaction times and undefined conditions, limiting their use as potential building blocks and therapeutic agents for diabetes treatment.
Innovation Solution
A process involving the reaction of 4a,7,8,8a-tetrahydropyrido[4,3-e]-1,4,2-dioxazine with lithium triethylborohydride or sodium triethylborohydride in the presence of tetrahydrofuran at controlled temperatures to produce 1,3-diazo-4-oxa-[3.3.1]-bicyclic derivatives, which can be used as GLP-1 receptor modulators for diabetes treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional synthesis methods are used for 1,3-diazo-4-oxa-[3.3.1]-bicyclic derivatives, then the compounds can be produced, but the reaction time is long and the process is inefficient
Solution Approach 1:
The patent changes the chemical parameters of the reaction by introducing specific reducing agents (lithium triethylborohydride or sodium triethylborohydride) and controlling the reaction conditions (temperature, solvent system). These parameter changes transform the conventional slow synthesis into a rapid one-step process, achieving high productivity while reducing reaction time from conventional multi-step lengthy procedures to a single efficient reaction step.
2Ease of manufacture
If conventional synthesis methods are used, then the derivatives can be obtained, but the manufacturing process is complex and economically disadvantageous
Solution Approach 1:
The patent segments the synthesis into a single well-defined step using specific reagents and conditions, rather than requiring multiple sequential reactions. This segmentation approach simplifies the manufacturing process by consolidating what would otherwise be a complex multi-step procedure into one efficient reaction, making the process easier to manufacture and more economically advantageous.
Solution Approach 2:
The patent uses lithium triethylborohydride or sodium triethylborohydride as an intermediary reducing agent that facilitates the transformation of 4a,7,8,8a-tetrahydropyrido[4,3-e]-1,4,2-dioxazine into the desired 1,3-diazo-4-oxa-[3.3.1]-bicyclic derivative. This specific intermediary enables the reaction to proceed under controlled conditions, simplifying the overall manufacturing process.
3Productivity
If the synthesis process is optimized for speed, then productivity increases, but reaction selectivity may be compromised
Solution Approach 1:
The patent carefully adjusts multiple parameters including the choice of reducing agent (lithium or sodium triethylborohydride), temperature control, and solvent system to achieve both high reaction rate and high selectivity. The specific parameter combination ensures that the rapid one-step synthesis maintains high manufacturing precision by favoring the desired product formation while minimizing side reactions.
Solution Approach 2:
The optimized synthesis process incorporates feedback control through monitoring reaction progress and adjusting conditions to maintain both speed and selectivity. The use of well-defined reagents and controlled conditions creates a self-regulating system that ensures high productivity while maintaining the selectivity needed for manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the rapid and selective synthesis of 1,3-diazo-4-oxa-[3.3.1]-bicyclic derivatives, enabling their use as effective GLP-1 receptor agonists for treating diabetes and related conditions, offering a more efficient and economically advantageous approach compared to previous methods.
Implementation Method 1
reaction of 4a,7,8,8a-tetrahydropyrido[4,3-e]-1,4,2-dioxazine with lithium triethylborohydride or sodium triethylborohydride to produce 1,3-diazo-4-oxa-[3.3.1]-bicyclic derivatives
Data Source
Figure 1
AI summary
The present invention relates to compounds having structural formula (I) wherein R1 and R2 are defined as set forth in the description. The invention also relates to a process for the manufacture of the above compounds of formula (I), wherein a 4a,7, 8, 8a-tetrahydropyrido[4,3-e]-1,4,2-dioxazine reacts with a hydride selected from the group consisting of: lithium triethylborohydride (LiBHEt3), sodium triethylborohydride (NaBHEt3), and lithium tetrahydroaluminate (LiAIH4), in the presence of tetrahydrofuran. Furthermore, the invention is aimed at the above compounds of formula (I), or pharmaceutically acceptable salts thereof, for use in medicine, preferably in the treatment of the diabetes and pathologies or conditions correlated thereto.